Hepatitis B Immune Globulin I.V. Approval Could Rely On Open-Label Studies, Historical Controls – FDA
This article was originally published in The Pink Sheet Daily
Executive Summary
The agency's briefing materials for the March 18 meeting of the Blood Products Advisory Committee note that prospective trials could be difficult because HBIGIV is currently used off-label in combination with antiviral drugs.